author-photo

Julia O. Davidova

4

Papers

10

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA

2020
Show All
- Source
- Cite
- Save
Citations (1)
Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile

2017 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Blinatumomab + Tyrosine Kinase Inhibitors in the Treatment of Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Patients - Clinical Efficacy and Peripheral Blood Lymphocytes Subpopulations Kinetics

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)